Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHA-022121 for acute treatment and prophylaxis of acquired C1-inhibitor deficiency angioedema
2021-000720-36Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucrictibant in acquired C1 esterase inhibitor deficiency (AAE) and C1 inhibitor deficiency (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Part 1: 3-symptom composite visual analogue scale score. Started May 2021; status: terminated.
02
Drugs
deucrictibant
03
Conditions
acquired C1 esterase inhibitor deficiency (AAE)C1 inhibitor deficiency
Beyond the preview
Go deeper on 2021-000720-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000720-36.